PDS Biotech Provides Business Update and Reports Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
PDS Biotechnology (PDSB) Misses Q3 EPS by 4c; Reports Cash and Cash Equivalents of $69.7M
November 10, 2021 7:29 AM ESTPDS Biotechnology (NASDAQ: PDSB) reported Q3 EPS of ($0.24), $0.04 worse than the analyst estimate of ($0.20).
For earnings history and earnings-related data on PDS Biotechnology (PDSB) click here.
... More